$7.75
4.39%
Downside
Day's Volatility :10.72%
Upside
6.63%
86.58%
Downside
52 Weeks Volatility :88.83%
Upside
16.76%
Period | Sight Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 52.08% | 6.5% | 0.0% |
6 Months | 76.1% | 7.1% | 0.0% |
1 Year | 1.65% | 9.8% | 0.0% |
3 Years | -77.85% | 14.2% | -20.2% |
Market Capitalization | 410.0M |
Book Value | $2.2 |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 6.5 |
Profit Margin | -67.18% |
Operating Margin TTM | -76.42% |
Return On Assets TTM | -19.32% |
Return On Equity TTM | -42.84% |
Revenue TTM | 81.5M |
Revenue Per Share TTM | 1.67 |
Quarterly Revenue Growth YOY | 2.3% |
Gross Profit TTM | 59.0M |
EBITDA | -53.8M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.03 |
EPS Estimate Next Year | -0.81 |
EPS Estimate Current Quarter | -0.28 |
EPS Estimate Next Quarter | -0.25 |
What analysts predicted
Downside of 16.13%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.5M | - |
Net Income | -14.3M | - |
Net Profit Margin | -189.77% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 23.3M | ↑ 210.07% |
Net Income | -25.9M | ↑ 81.03% |
Net Profit Margin | -110.8% | ↑ 78.97% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 27.6M | ↑ 18.38% |
Net Income | -34.7M | ↑ 34.11% |
Net Profit Margin | -125.52% | ↓ 14.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 49.0M | ↑ 77.12% |
Net Income | -63.0M | ↑ 81.48% |
Net Profit Margin | -128.61% | ↓ 3.09% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 71.3M | ↑ 45.7% |
Net Income | -86.2M | ↑ 36.98% |
Net Profit Margin | -120.9% | ↑ 7.71% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 81.1M | ↑ 13.63% |
Net Income | -55.5M | ↓ 35.59% |
Net Profit Margin | -68.53% | ↑ 52.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 20.5M | ↑ 9.99% |
Net Income | -16.9M | ↓ 23.94% |
Net Profit Margin | -82.3% | ↑ 36.72% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 8.37% |
Net Income | -17.1M | ↑ 0.95% |
Net Profit Margin | -90.67% | ↓ 8.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↑ 24.69% |
Net Income | -14.8M | ↓ 13.55% |
Net Profit Margin | -62.86% | ↑ 27.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.0M | ↓ 14.75% |
Net Income | -13.0M | ↓ 11.65% |
Net Profit Margin | -65.15% | ↓ 2.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 6.29% |
Net Income | -10.7M | ↓ 17.98% |
Net Profit Margin | -57.02% | ↑ 8.13% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 19.3M | ↑ 2.74% |
Net Income | -16.3M | ↑ 52.15% |
Net Profit Margin | -84.43% | ↓ 27.41% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 8.1M | - |
Total Liabilities | 37.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.7M | ↑ 279.8% |
Total Liabilities | 85.4M | ↑ 130.53% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 72.8M | ↑ 136.84% |
Total Liabilities | 161.7M | ↑ 89.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 280.2M | ↑ 284.84% |
Total Liabilities | 48.1M | ↓ 70.26% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 213.1M | ↓ 23.95% |
Total Liabilities | 53.0M | ↑ 10.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 166.7M | ↓ 21.79% |
Total Liabilities | 46.4M | ↓ 12.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 213.1M | ↓ 5.4% |
Total Liabilities | 53.0M | ↑ 1.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 196.6M | ↓ 7.71% |
Total Liabilities | 50.3M | ↓ 5.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 185.3M | ↓ 5.77% |
Total Liabilities | 49.2M | ↓ 2.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 176.6M | ↓ 4.67% |
Total Liabilities | 49.6M | ↑ 0.84% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 166.7M | ↓ 5.66% |
Total Liabilities | 46.4M | ↓ 6.33% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 155.6M | ↓ 6.66% |
Total Liabilities | 46.4M | ↓ 0.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.5M | - |
Investing Cash Flow | -570.0K | - |
Financing Cash Flow | 12.2M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.0M | ↑ 72.69% |
Investing Cash Flow | -672.0K | ↑ 17.89% |
Financing Cash Flow | 42.7M | ↑ 249.62% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.2M | ↑ 28.71% |
Investing Cash Flow | -953.0K | ↑ 41.82% |
Financing Cash Flow | 73.4M | ↑ 72.04% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -52.5M | ↑ 63.3% |
Investing Cash Flow | -813.0K | ↓ 14.69% |
Financing Cash Flow | 252.5M | ↑ 244.04% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.0M | ↑ 44.59% |
Investing Cash Flow | -970.0K | ↑ 19.31% |
Financing Cash Flow | 1.2M | ↓ 99.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.5M | ↓ 23.23% |
Investing Cash Flow | -129.0K | ↓ 52.57% |
Financing Cash Flow | 812.0K | ↑ 336.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -17.4M | ↑ 12.13% |
Investing Cash Flow | -126.0K | ↓ 2.33% |
Financing Cash Flow | -156.0K | ↓ 119.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.5M | ↓ 22.4% |
Investing Cash Flow | -97.0K | ↓ 23.02% |
Financing Cash Flow | 766.0K | ↓ 591.03% |
Sell
Neutral
Buy
Sight Sciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Sight Sciences Inc | 27.06% | 76.1% | 1.65% | -77.85% | -76.03% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Sight Sciences Inc | NA | NA | NA | -1.03 | -0.43 | -0.19 | NA | 2.2 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Sight Sciences Inc | Buy | $410.0M | -76.03% | NA | -67.18% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Sight Sciences Inc
Revenue is up for the last 2 quarters, 18.75M → 19.26M (in $), with an average increase of 2.7% per quarter
Netprofit is down for the last 2 quarters, -10.69M → -16.26M (in $), with an average decrease of 52.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 40.1%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 146.8%
Bank of America Corp
UBS Group AG
Jackson Square Partners, LLC
Vanguard Group Inc
BlackRock Inc
JPMorgan Chase & Co
sight sciences, inc. is a medical devices company based out of menlo park, california, united states.
Organization | Sight Sciences Inc |
Employees | 214 |
CEO | Mr. Paul Badawi |
Industry | Healthcare |